Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Basic) (2016 - 2026)

Corvus Pharmaceuticals' EPS (Basic) history spans 12 years, with the latest figure at -$0.15 for Q1 2026.

  • Quarterly EPS (Basic) fell 171.43% to -$0.15 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$0.52 through Mar 2026, up 16.13% year-over-year, with the annual reading at -$0.19 for FY2025, 81.37% up from the prior year.
  • EPS (Basic) came in at -$0.15 for Q1 2026, roughly flat from -$0.15 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.21 in Q1 2025 to a low of -$0.6 in Q3 2024.
  • The 5-year median for EPS (Basic) is -$0.15 (2025), against an average of -$0.16.
  • Year-over-year, EPS (Basic) plummeted 400.0% in 2024 and then skyrocketed 275.0% in 2025.
  • Corvus Pharmaceuticals' EPS (Basic) stood at -$0.21 in 2022, then soared by 38.1% to -$0.13 in 2023, then decreased by 23.08% to -$0.16 in 2024, then increased by 6.25% to -$0.15 in 2025, then changed by 0.0% to -$0.15 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's EPS (Basic) are -$0.15 (Q1 2026), -$0.15 (Q4 2025), and -$0.12 (Q3 2025).